ADVERSE EFFECTS OF LONG-TERM CORTICOSTEROID THERAPY OF NEPHROTIC SYNDROME IN CHILDREN
https://doi.org/10.15690/pf.v14i3.1740
Abstract
Background: Long-term corticosteroid therapy in children leads to plenty of adverse effects with negative influence on health. Objective: analysis of adverse effects of corticosteroids in children with steroid-sensitive nephrotic syndrome and development of recommendations of their early detection.
Methods: A retrospective study is conducted on children with this syndrome aged 3–18 who applied to Voronezh Regional Children’s Clinical Hospital № 1 in 2011–2014. Complications of corticosteroid therapy revealed during clinical examination of children were taken into account. Data on 118 healthy children examined in 2012–2014 were used to calculate integral index.
Results: The study analyses treatment results of 18 children who received glucocorticosteroids during 6 months before hospitalization and 13 children who were withdrawn from glucocorticosteroids for 6 months or more before hospitalization. Among adverse reactions in group 1 there prevailed overweight/obesity (78%), reactive pancreatitis (72%), leukemoid reactions (67%), liver damage (61%), Cushingoid syndrome (44%), chronic gastroduodenitis (33%). Hyperglycemia (11%), hypertension (6%) and infection (6%) were less common. In group 2 only 2 (15%) patients had chronic gastroduodenitis, other complications were not documented. Indices that change in children with nephrotic syndrome during corticosteroid treatment (body mass index, blood serum glucose and amylase) were measured by a single scale using modifications coefficients. Average value of the coefficients is suggested to be a new diagnostic criterion (metabolic reaction index) which allows to reveal corticosteroid adverse effects before any clinical manifestations.
Conclusion: Most adverse reactions of glucocorticosteroids are short-term and continue after 6 months in a small number of patients.
About the Authors
T. L. NastaushevaRussian Federation
O. A. Zhdanova
Russian Federation
G. A. Batishcheva
Russian Federation
T. G. Zvyagina
Russian Federation
References
1. pediatr-russia.ru [интернет]. Клинические рекомендации. Нефротический синдром у детей [доступ от 03.05.2017]. Доступ по ссылке http://www.pediatr-russia.ru/sites/default/files/file/kr_nefr.pdf.
2. kdigo.org [интернет]. Клинические практические рекомендации KDIGO по лечению гломерулонефритов. Перевод. 2014. 239 с. [KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):259–274. (Translated in Russian).] [доступ от 03.05.2017]. Доступ по ссылке http://kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20GN%20Russian%20Full%20Text.pdf.
3. Обухова В.А., Длин В.В. Факторы риска часто рецидивирующего течения стероид-чувствительного нефротического синдрома у детей // Российский вестник перинатологии и педиатрии. — 2014. — Т.59. — №6 — С. 79–83. [Obukhova VA, Dlin VV. Risk factors of frequent relapses of steroid-sensitive nephrotic syndrome in children. Rossiiskii vestnik perinatologii i pediatriii (Russian Bulletin of Perinatology and Pediatrics). 2014;59(6):79–83. (In Russ).]
4. Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015;(3):CD001533. doi: 10.1002/14651858.CD001533.pub5.
5. Larkins N, Kim S, Craig J, Hodson E. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch Dis Child. 2016;101(4):404–408. doi: 10.1136/archdischild-2015-308924.
6. Цыгин А.Н., Комарова О.В., Сергеева Т.В., и др. Нефротический синдром // Педиатрическая фармакология. — 2006. — Т.3. — №5 — С. 41–47. [Tsygin AN, Komarova OV, Sergeeva TV, et al. Nephrotic syndrome. Pediatric pharmacology. 2006;3(5):41–47. (In Russ).]
7. who.int [Internet]. WHO growth reference 5–19 years. Application tools. WHO AnthroPlus software [cited 2017 May 3]. Available from: http://www.who.int/growthref/tools/en/.
8. Заявка на изобретение № 2016139397 от 07.10.2016 г. [The application for the invention № 2016139397 dated 07 Oct 2016 (In Russ).] Доступно по: http://www1.fips.ru/fips_servl/fips_servlet. Ссылка активна на 03.05.2017.
9. Федеральные клинические рекомендации (протоколы) по ведению детей с эндокринными заболеваниями / Под ред. Дедова И.И., Петерковой В.А. — М.: Практика; 2014. С. 167–168. [Federal’nye klinicheskie rekomendatsii (protokoly) po vedeniyu detei s endokrinnymi zabolevaniyami. Ed by Dedov I.I., Peterkova V.A. Moscow: Practika; 2014. P. 167–168. (In Russ).]
10. Ландышев Ю.С. Механизмы действия и основные терапевтические эффекты глюкокортикоидов // Амурский медицинский журнал. — 2014. — №1 — С. 10–29. [Landyshev YS. Mechanisms of action and therapeutic effects of basic glucocorticoids. Amur Medical Journal. 2014;(1):10–29. (In Russ.)]
11. Страчунский Л.С., Козлов С.Н. Глюкокортикоидные препараты. Методическое пособие [интернет]. НИИАХ СГМА; 2003 [Strachunskii LS, Kozlov SN. Glyukokortikoidnye preparaty. Metodicheskoe posobie. NIIAKh SGMA; 2003. (In Russ).] [доступ от 03.05.2017]. Доступ по ссылке http://www.antibiotic.ru/rus/all/metod/gk/.
12. Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? Nat Clin Pract Nephrol. 2008;4(10):550–559. doi: 10.1038/ncpneph0915.
13. Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long-course oral corticosteroids in children. PLoS One. 2017;12(1):e0170259. doi: 10.1371/journal.pone.0170259.
14. Ishikura K, Yoshikawa N, Nakazato H, et al. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol. 2015;30(3):459–468. doi: 10.1007/s00467-014-2955-8.
15. Kyrieleis HA, Löwik MM, Pronk I, et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 2009;4(10):1593–600. doi: 10.2215/CJN.05691108.
16. Hjorten R, Anwar Z, Reidy KJ. Long-term outcomes of childhood onset nephrotic syndrome. Front Pediatr. 2016;4:53. doi: 10.3389/fped.2016.00053.
17. Бекмурзаева Г.Б., Полещук Л.А. Поражение поджелудочной железы при нефротическом синдроме // Российский вестник перинатологии и педиатрии. — 2012. — Т.57. — №1 — С. 54–57. [Bekmurzayeva GB, Poleshchuk LA. Pancreatic damage in nephrotic syndrome. Rossiiskii vestnik perinatologii i pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2012;57(1):54–57. (In Russ).]
18. Foster BJ, Shults J, Zemel BS, Leonard MB. Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2006;21(7):973–980. doi: 10.1007/s00467-006-0100-z.
Review
For citations:
Nastausheva T.L., Zhdanova O.A., Batishcheva G.A., Zvyagina T.G. ADVERSE EFFECTS OF LONG-TERM CORTICOSTEROID THERAPY OF NEPHROTIC SYNDROME IN CHILDREN. Pediatric pharmacology. 2017;14(3):165-172. (In Russ.) https://doi.org/10.15690/pf.v14i3.1740